atorvastatin has been researched along with lycopene in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, WL; Clapper, ML; Cooper, HS | 1 |
| Elawady, AS; Elnagar, GM; Elseweidy, MM; Sobh, MS | 1 |
1 review(s) available for atorvastatin and lycopene
| Article | Year |
|---|---|
Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention.
Topics: Aberrant Crypt Foci; Adenoma; Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; Aspirin; Atorvastatin; Carcinogenesis; Catechin; Clinical Trials as Topic; Colon; Colonoscopy; Colorectal Neoplasms; Dietary Supplements; Disease Models, Animal; Humans; Intestinal Mucosa; Lycopene; Mice; Mutation; Treatment Outcome | 2020 |
1 other study(ies) available for atorvastatin and lycopene
| Article | Year |
|---|---|
Lycopene ameliorates hyperlipidemia via potentiation of AMP-activated protein kinase and inhibition of ATP-citrate lyase in diabetic hyperlipidemic rat model.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Atorvastatin; ATP Citrate (pro-S)-Lyase; Biomarkers; Coenzyme A; Diabetes Mellitus; Fatty Acid Synthases; Glutathione; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lycopene; Malondialdehyde; Multienzyme Complexes; Oxo-Acid-Lyases; Rats; Streptozocin; Tumor Necrosis Factor-alpha | 2022 |